Pregnancy and MS: What Cladribine Exposure May Mean

Credibility

Interest

Key Takeaway

This study looked at babies born after exposure to a medicine called cladribine around pregnancy and found no clear increase in major birth defects, but data are limited so caution is still advised.

What They Found

Researchers collected reports of pregnancies where the mother had taken cladribine, a drug used to treat multiple sclerosis (MS). They counted how many pregnancies led to live births, miscarriages (spontaneous abortion), abortions chosen by the parent (elective termination), ectopic pregnancies (when the embryo implants outside the womb), stillbirths, and whether babies had major congenital anomalies (serious birth defects). The main result was that the number of major birth defects was not higher than what is generally seen in the population, but the total number of cases was small. Because cladribine is not recommended during pregnancy, most people avoid using it while trying to conceive, so reports are limited and come mostly from accidental exposures or situations where people became pregnant after treatment. The study gives some reassurance but cannot fully rule out rare risks because there weren't enough pregnancies to be certain.

Who Should Care and Why

People with MS who are planning a family or who might become pregnant should care because this study informs decisions about timing MS treatments and pregnancy. Caregivers and partners will want to know whether a recent dose of cladribine could affect a future pregnancy; the study suggests risks are not clearly higher, but certainty is low. Neurologists and other healthcare providers should use this information when discussing family planning, balancing disease control with pregnancy safety—like deciding when to pause or delay a treatment. Think of it like checking the weather before a trip: the report helps guide plans but doesn’t guarantee perfect conditions. The people who benefit most are those making choices about starting or stopping cladribine around the time of conception, because the findings help weigh potential risks and benefits.

Important Considerations

The study had a small number of pregnancies, so rare problems could be missed—this matters because a low number of reports makes findings less certain. Most pregnancies were not planned during treatment, and people are advised not to take cladribine while pregnant, so the data come from accidental exposures and may not represent all situations. Because of these limits, doctors still recommend being cautious: follow guidance on how long to wait after treatment before trying to conceive and discuss plans with your MS care team.

Categories:

Pregnancy and MS is not an allowed category Clinical Trials Living with MS

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Neurology and therapy often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News